Precigen (NASDAQ:PGEN) shares are trading higher on Wednesday on continued upward momentum after the company announced the first patient has been dosed its Phase I/II study of PRGN-2009 to treat HPV-associated cancers.
Precigen's stock traded up 10.02% at $5.38 per share at the time of publication on Wednesday. The stock has a 52-week high of $7.28 and a 52-week low of $1.26.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
